Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that patients using dupilumab for atopic dermatitis or chronic rhinosinusitis with nasal polyps may experience new-onset or worsening paradoxical alopecia areata, potentially due to unopposed Th1/Th17 immune activity following Th2 pathway blockade.

This study observed sustained hair regrowth in some patients with alopecia areata and improvement in vitiligo symptoms, indicating a potential role for dupilumab in treating these conditions, particularly when associated with atopic dermatitis.

This case study reports a successful use of co-trimoxazole in treating a 13-year-old girl with symptoms suggestive of autoimmune disorders and relapsing polychondritis.

This study found that mycophenolate mofetil was associated with higher response rates and lower rates of serious side effects, including a lower mortality rate, compared to cyclophosphamide in lupus nephritis treatment.

This article reviews current treatments for alopecia areata, discussing the potential role of JAK inhibitors and noting the need for further clinical trials, but it reports no new results.

Mini pulse corticosteroid therapy with oral dexamethasone is effective and has fewer side effects for treating extensive alopecia areata.

This study found that the MD-3 antibody significantly improved the survival of hair follicle allografts in nonhuman primates by reducing T-cell infiltration.

Topical imiquimod is as effective as 5-fluorouracil for treating actinic keratosis, with about a 5% risk of it turning into squamous cell carcinoma.

This case study reports significant improvement in severe atopic dermatitis and alopecia areata symptoms in a patient treated with dupilumab, highlighting the potential for patient selection in optimizing therapeutic outcomes.

This study found that some synthesized heterocyclic derivatives showed promising 5α-reductase inhibitor, antiviral, and anti-tumor activities, surpassing several reference drugs in effectiveness.

In this review, researchers explored the design of composite biomaterials for immunomodulation and their potential to influence immune cell behavior, which could be leveraged for treating diseases like cancer and improving tissue regeneration, while also addressing translational challenges such as biocompatibility and safety.

In this study, researchers using multistate modeling reported that patients with psoriasis treated with brodalumab had a higher probability of achieving and maintaining a therapeutic response compared to those treated with ustekinumab over 52 weeks, based on absolute PASI measurements.

This study found that administering an S1PR 1&4 modulator reduced alopecia areata lesion size and decreased CD8+ T cell infiltration in mice, suggesting potential as a treatment for this condition.

In this study, Polygonum multiflorum Radix promoted hair growth in mice, with oral administration being more effective, likely through FGF-7, while topical application favored SHH-related mechanisms.

Dithranol reduces inflammation in alopecia areata by lowering certain immune responses.

In this study, patients with active lymphocytic cicatricial alopecia showed significant improvement using a three-stage treatment regimen involving Tofacitinib, Apremilast, and Crisaborole, with 93.5% experiencing marked improvement and only three mild adverse events reported.

This study reports a case of a 59-year-old female with refractory follicular mucinosis and diffuse scalp alopecia who achieved complete clinical remission following treatment with a combination of topical tacalcitol and photodynamic therapy.

This case report details the development of a psoriasiform rash and inflammatory alopecia in a 29-year-old man with severe atopic dermatitis following dupilumab treatment. The authors observed hair regrowth and eczema control after discontinuing dupilumab and beginning treatment with abrocitinib.

This study found that 2MbisP increases epidermal thickening more rapidly than atRA in rhino mice, while both compounds similarly reduce utricle size.

This animal study observed that treatment with the S1PR modulator NXC736 significantly reduced lesion area and CD8+ T cell infiltration in mice with alopecia areata, suggesting its potential as a promising therapy for the condition.

In a hair-growth mouse model, this study reported that the novel AR antagonist candidate 39, derived from structural optimization of 14-P1, achieved similar efficacy to pyrilutamide with faster response and maintained safety, demonstrating potent AR antagonism and favorable pharmacokinetics with lower systemic toxicity risk.

This review discusses AMH and ovarian morphology as complementary markers in diagnosing PCOS/PMOS and reports no new clinical results, highlighting the need for a multidomain approach in diagnosis and treatment.

In this study, combining baricitinib and prednisone effectively achieved complete hair regrowth in seven out of eight women with very severe alopecia areata, contrasting with less effective results from each drug used alone.

This study tested a hydrogel microneedle patch delivering T reg attractants in mice with alopecia, finding it boosted regulatory T cell numbers at the site, leading to hair regrowth without causing peripheral immunosuppression, suggesting a potential new approach for autoimmune skin disease treatment.

This study reports a case where cyclosporine effectively treated a 51-year-old woman with idiopathic follicular mucinosis resistant to other therapies, suggesting its potential as an option for refractory cases.

In this study, baricitinib treatment over an average of 18.5 months resulted in a 72% reduction in alopecia severity scores among patients aged 65 or older, with mild adverse effects and no severe complications reported.

This study surveyed patients with idiopathic inflammatory myopathy and found that glucocorticoid treatment commonly leads to adverse effects, particularly sleep disturbance, mood swings, and weight gain, with more severe effects reported by female patients.

This review assessed the clinical and cost-effectiveness of baricitinib, an oral treatment for severe alopecia areata in adults, to inform Canadian reimbursement recommendations, excluding Quebec.